ReviewMovement disorders clinical practice
Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage?
Review in Movement disorders clinical practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Impact of deep brain stimulation on urogenital function in Parkinson's disease: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Two dopaminergic systems, one bladder: recognising a therapy-resistant urinary phenotype in Parkinson's disease.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026Article
- Lower Urinary Tract Symptoms as Diagnostic Clues in Parkinsonism: A Practical Framework for Neurologists.Movement disorders clinical practice · 2026Review
- Clinical Studies Using Intranasal Therapies for Parkinson's Disease: A Review.Advanced pharmaceutical bulletin · 2026Review
- Influence of autonomic dysfunction on sleep disturbance in drug-naïve patients with Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Approach to Cardiovascular Autonomic Dysfunction in Patients with Synucleinopathies.Movement disorders clinical practice · 2025Review
- A reset on our reclined position-a call to prioritize neurogenic supine hypertension in the synucleinopathies.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025Review
- Insomnia in Parkinson's Disease: Causes, Consequences, and Therapeutic Approaches.Molecular neurobiology · 2025Review
- Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson's disease.Clinical parkinsonism & related disorders · 2025Article
- Circadian rhythm disruption: a potential trigger in Parkinson's disease pathogenesis.Frontiers in cellular neuroscience · 2024Review
- The Impact of Polypharmacy on Management of Lower Urinary Tract Symptoms in Parkinson's Disease.Drugs & aging · 2023Review
- Nocturia and Sleep in Parkinson's Disease.Journal of personalized medicine · 2023Article
- Circadian disruption and sleep disorders in neurodegeneration.Translational neurodegeneration · 2023Review
- Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.Patient related outcome measures · 2023Review
- Circadian rhythms in neurodegenerative disorders.Nature reviews. Neurology · 2022Review
- Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering.Scientific reports · 2021Article
- Lower urinary tract dysfunction in Parkinsonian syndromes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.CNS drugs · 2021Review
- SURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease.Brain sciences · 2021Article
- In Silico design of AVP (4-5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundNocturia is one of the commonest nonmotor symptoms in Parkinson's disease (PD) and has a significant impact on quality of life both for patients and their carers. There exists a relation between nocturia and poor sleep quality, falls, and institutionalization. Nocturia may manifest as a result of reduced functional bladder capacity or nocturnal polyuria; however, most often the cause is multifactorial. Disorders of circadian rhythm regulation are known to occur with sleep disturbances in PD may also contribute to nocturia. METHODS AND
resultsIn this review, an overview of the assessment and management of nocturia in patients with PD is presented. History taking, medication review, and a bladder diary form the cornerstone of the evaluation. Urinalysis, ultrasonography, and urodynamic studies help to assess the cause for lower urinary tract symptoms and exclude concomitant pathologies, such as bladder outlet obstruction. Antimuscarinic medications are the first-line treatment for the overactive bladder; however, caution is needed when using these medications in individuals predisposed to cognitive impairment. Desmopressin is effective for managing nocturnal polyuria.
conclusionsAn individualized approach is recommended to optimize the management of nocturia in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.